Showing results (141-150 of 243) with videos related to
Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i>-mutant Non-small Cell Lung CancerHelena A Yu, Luis G Paz-Ares, James Chih-Hsin Yang, et al.Journal of Crohn'S & Colitis|October 3, 2017
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological EntitiesClélia Coutzac, Julien Adam, Emilie Soularue, et al.European Journal of Cancer (Oxford, England : 1990)|May 11, 2020
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF<sup>V600E</sup> non-small cell lung cancerFrancesco Facchinetti, Ludovic Lacroix, Laura Mezquita, et al.The Lancet. Oncology|June 11, 2016
Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trialDavid Planchard, Benjamin Besse, Harry J M Groen, et al.European Journal of Cancer (Oxford, England : 1990)|November 23, 2025
The rechallenge benefit score: A clinical decision tool for patients progressing after immunotherapyCaroline Plazy, Mohamed Boussena, Linh Nguyen Phuong, et al.JCI Insight|May 5, 2022
Targeting genome integrity dysfunctions impedes metastatic potency in non-small cell lung cancer circulating tumor cell-derived explantsTala Tayoun, Vincent Faugeroux, Marianne Oulhen, et al.Future Oncology (London, England)|February 15, 2021
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancerMarina C Garassino, Luis Paz-Ares, Rina Hui, et al.Cancers|December 17, 2020
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung CancerArthur Geraud, Laura Mezquita, Edouard Auclin, et al.The Lancet. Oncology|January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialArnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 21, 2019
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal MetastasesRonan Flippot, Pamela Biondani, Edouard Auclin, et al.Pageof 25